Yuhan signs $1.25 billion licensing deal with Janssen
Lasertinib(GNS-1480), discovered by Genosco, was out-licensed to Janssen.
Early results from a 3rd gen EGFR-TKI in advanced NSCLC
Dr. Cho speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase I/II trial of lazertinib(GNS-1480, YH25448), a highly selective and irreversible investigational 3rd-generation EGFR-TKI.
YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results
Genosco's pipeline GNS-1480 (YH25448) was presented at ASCO 2018. *ASCO stands for American Society of Clinical Oncology Annual Meeting.
YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results
ASCO 2018 Poster Board: #356 • Abstract 9033; Byoung Chul Cho - First Author, Severence Hospital
Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448(GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018
Business Wire * May 16, 2018; Abstract - https://meetinglibrary.asco.org/record/161036/abstract
YH25448, an irreversible 3rd-generation EGFR TKI, exhibits superior anticancer effects with potent brain BBB penetration in NSCLC
Genosco's pipeline GNS-1480 (YH25448) was presented at AACR Annual meeting 2018. *AACR stands for American Association for Cancer Research.
Pipeline Overview
Pipeline Overview Our http://www.clinicabalaciart.com/ includes SYK, FLT3/AXL, EGFR mutants (single, double and http://www.clinicabalaciart.com/), and FGFR4 signal network related disease pathways. Genosco’s core competence comes from its know-how in generating canadian brand viagra of interest. Our most advanced pipeline is SKI-O-703, a selective SYK inhibitor for rheumatoid arthritis (RA), immune thrombocytopenia (ITP) and systemic lupus [...]
Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer
This article was published on Cancer Research - AACR Journals, doi: 10.1158/0008-5472.CAN-16-2432 in February 2017.
YH25448, a highly selective 3rd generation EGFR TKI, exhibits superior survival benefit over osimertinib in mice with brain metastases of NSCLC
Genosco's pipeline GNS-1480 (Yuhan code: YH25448) was presented at the IASLC 17th World Conference on Lung Cancer in December 2016. *IASLC stands for International Association for the Study of Lung Cancer.